Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma
Status:
Not yet recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the feasibility and tolerability of
neo-adjuvant/adjuvant Darovasertib on uveal melanoma patients.
Who is it for? Patients may be eligible to join this study with high-risk uveal melanoma and
planned to undergo enucleation
Study details:
Eligible patients will undergo up to 4 weeks of treatment with Darovasertib (300mg, twice a
day as a starting dose) after fulfilling inclusion/exclusion criteria and consent. Select
patients will undergo adjuvant treatment for 6 months based on their initial response.
It is hoped that this research will provide insight into the safety and tolerability of
Darovasertib. Furthermore, it aims to document the pharmacodynamic and pharmacokinectic
effects of Darovasertib on uveal melanoma patients.